• SIRT4 Regulation of Glutamine Metabolism Mitigates Liver Fib

  2026-05-09

  This study demonstrates that SIRT4 modulates glutamine metabolism in hepatic stellate cells (HSCs), reducing their activation and attenuating liver fibrosis progression. By elucidating the SIRT4–GDH axis, the work provides a mechanistic basis for targeting mitochondrial metabolic pathways in chronic liver disease.

• SM-164: Bivalent Smac Mimetic Workflows for Apoptosis Assays

  2026-05-08

  SM-164, a bivalent Smac mimetic from APExBIO, enables precise and rapid induction of apoptosis in cancer research models by antagonizing IAPs and enhancing TNFα-dependent cell death. This article details optimized experimental protocols, troubleshooting strategies, and translates new signalosome insights into actionable workflow enhancements for apoptosis assays.

• CDC42 Regulates HBV Entry via NTCP Trafficking and Macropino

  2026-05-08

  This study demonstrates that active CDC42 promotes hepatitis B virus (HBV) entry into hepatocytes by facilitating NTCP translocation to the plasma membrane via Rab11-dependent recycling and enabling macropinocytosis as a parallel entry route. These findings reveal previously unrecognized mechanisms of HBV infection and suggest potential therapeutic targets within Rho GTPase signaling.

• Polyvalent Vaccines Target Tumor-Associated Bacteria to Bloc

  2026-05-07

  Kang et al. introduce a polyvalent nanovaccine platform that selectively eliminates tumor-promoting bacteria, significantly reducing breast cancer metastasis. This approach demonstrates that altering the tumor microbiome is a viable strategy for enhancing antitumor immunity and improving clinical outcomes.

• Anemoside B4 Inhibits NLRP3 Inflammasome in DSS Colitis Mode

  2026-05-07

  This study demonstrates that Anemoside B4 (AB4) alleviates DSS-induced colitis in mice by targeting macrophage CD1d-dependent NLRP3 inflammasome activation, with mechanistic links to suppressed AKT-STAT1-PRDX1-NF-κB signaling. These findings offer new insights into inflammation research and support the use of selective NF-κB inhibitors for dissecting similar pathways.

• Trehalose-Loaded LNPs Advance mRNA Vaccine Stability Strateg

  2026-05-06

  A recent study introduces a dual-function trehalose approach in lipid nanoparticle (LNP) formulations to enhance mRNA stability, directly addressing the in vitro-in vivo efficacy gap in mRNA vaccines. This strategy promises more reliable storage and delivery, with broad implications for translational mRNA research and vaccine development.

• Guanabenz Acetate: Precision Modulation for Translational Re

  2026-05-06

  Explore how Guanabenz Acetate, a high-purity α2-adrenergic receptor agonist, is reshaping translational research at the intersection of GPCR signaling and innate immune modulation. This article integrates mechanistic insight with practical strategy, referencing key advances in viral innate immunity evasion, and positions APExBIO’s product as a gold-standard tool for rigorous, innovative experimental design.

• KPNB1-ATF4-BNIP3 Mitophagy Axis Drives Odontoblast Different

  2026-05-05

  Zhang et al. (2024) identify a KPNB1-ATF4-BNIP3 signaling axis that regulates BNIP3-dependent mitophagy, which is essential for odontoblastic differentiation of dental pulp stem cells (DPSCs). Their mechanistic study provides new molecular insights for regenerative endodontics and highlights mitophagy as a therapeutic target.

• Pentoxifylline: Translational Immunomodulation and Optimized

  2026-05-05

  Explore how Pentoxifylline, a leading phosphodiesterase inhibitor, enables translational immunomodulation through cAMP pathway targeting and advanced assay optimization. This article delivers unique, protocol-focused insights for inflammation and infectious disease research.

• Transmission Dynamics of Carbapenemase Genes in CREC in Guan

  2026-05-04

  This study systematically characterizes carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) from multiple hospitals in Guangdong, China during the COVID-19 era. The findings reveal high prevalence, plasmid-mediated mobility, and multidrug resistance linked to blaNDM-1, with implications for infection control and clinical research.

• Arctigenin Inhibits HCC via PI3K/AKT Pathway: Mechanistic In

  2026-05-04

  This study reveals that arctigenin from Saussurea medusa inhibits hepatocellular carcinoma (HCC) proliferation and induces apoptosis by targeting the PI3K/AKT pathway. The integration of network pharmacology, molecular docking, and in vitro/in vivo validation provides robust mechanistic understanding and highlights arctigenin’s potential as a plant-derived therapeutic agent for HCC.

• Quizartinib (AC220): Precision FLT3 Inhibition in AML Workfl

  2026-05-03

  Quizartinib (AC220) empowers acute myeloid leukemia research with nanomolar FLT3 inhibition, exceptional selectivity, and proven in vivo performance. This guide delivers actionable workflows, troubleshooting strategies, and highlights innovations from the latest FLT3 resistance studies to accelerate translational breakthroughs.

• Tariquidar (XR9576) for Precision Drug Resistance Research

  2026-05-02

  Tariquidar (XR9576) enables robust, reproducible inhibition of P-glycoprotein even in complex, high-viscosity tumor models, making it essential for advanced transporter-mediated drug disposition and chemoresistance studies. This guide provides actionable workflows, troubleshooting strategies, and insights directly informed by cutting-edge research on the mechanobiological drivers of multidrug resistance.

• FGFR and PI3K/AKT Cross-Talk Regulates Periostin in HER2+ Br

  2026-05-01

  Labrèche et al. (2021) revealed that periostin expression in HER2-positive breast cancer cells is regulated through a complex cross-talk between FGFR, TGFβ, and PI3K/AKT signaling pathways. This mechanistic insight clarifies how tumor epithelial cells acquire periostin expression, with implications for targeting tumor progression and metastasis.

• Dasatinib Monohydrate (BMS-354825): Precision in Imatinib-Re

  2026-05-01

  Explore how Dasatinib Monohydrate (BMS-354825) advances imatinib-resistant leukemia and personalized cancer research by enabling precise kinase inhibition in complex, patient-specific assembloid models. This in-depth analysis highlights workflow parameters and cutting-edge applications.

14611 records 1/975 page Next 12345 下5页 Last page